GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

vizenpistat   Click here for help

GtoPdb Ligand ID: 14076

Synonyms: SR-8541A | SR8541A
Compound class: Synthetic organic
Comment: Vizenpistat is the INN for a ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitor that was included in WHO INN proposed list 133 (10th July 2025). The chemical structure is a match for compound 015 in patent WO2021158829A1 [1]. This is predicted to be the INN for the orally bioavailable ENPP1 inhibitor SR-8541A (Stingray Therapeutics) which has begun first-in-human trial [2].
ENPP1 is a negative regulator of the cGAS-STING-2'3' cGAMP pathway, and its inhibition is proposed to re-activate the innate anti-tumour immune response in the adenosine immunosuppressed tumour microenvironment.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 118.2
Molecular weight 367.43
XLogP -0.8
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC1=CC2=C(N=CN=C2C=C1OC)N3CCCN(CC3)S(=O)(=O)N
Isomeric SMILES COC1=C(C=C2C(=C1)C(=NC=N2)N3CCCN(CC3)S(=O)(=O)N)OC
InChI InChI=1S/C15H21N5O4S/c1-23-13-8-11-12(9-14(13)24-2)17-10-18-15(11)19-4-3-5-20(7-6-19)25(16,21)22/h8-10H,3-7H2,1-2H3,(H2,16,21,22)
InChI Key KZXIIZCLNZSOEZ-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
SR-8541A (Stingray Therapeutics) was progressed to first-in-human trial [2], and will be evaluated in patients with advanced/metastatic solid tumours, with and without additional immune checkpoint inhibitor therapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06063681 A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors Phase 1 Interventional Stingray Therapeutics
NCT06589440 Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) Phase 2 Interventional Stingray Therapeutics